Gremese, Elisa
 Distribuzione geografica
Continente #
NA - Nord America 6.252
EU - Europa 5.430
AS - Asia 2.386
AF - Africa 97
OC - Oceania 29
SA - Sud America 29
Continente sconosciuto - Info sul continente non disponibili 20
Totale 14.243
Nazione #
US - Stati Uniti d'America 6.161
IT - Italia 1.025
SE - Svezia 1.015
CN - Cina 961
DE - Germania 920
SG - Singapore 694
FR - Francia 492
PL - Polonia 492
IE - Irlanda 391
UA - Ucraina 366
ID - Indonesia 234
GB - Regno Unito 197
IN - India 162
FI - Finlandia 161
RU - Federazione Russa 129
CA - Canada 78
BE - Belgio 71
TR - Turchia 66
CI - Costa d'Avorio 49
HK - Hong Kong 45
IR - Iran 39
JP - Giappone 38
CZ - Repubblica Ceca 28
AU - Australia 27
SA - Arabia Saudita 27
CH - Svizzera 25
NL - Olanda 25
VN - Vietnam 19
PH - Filippine 13
ES - Italia 12
EU - Europa 12
PK - Pakistan 12
ZA - Sudafrica 12
EG - Egitto 10
GR - Grecia 10
MY - Malesia 10
RO - Romania 10
AT - Austria 9
CL - Cile 9
IL - Israele 9
KR - Corea 9
BR - Brasile 8
A2 - ???statistics.table.value.countryCode.A2??? 7
BD - Bangladesh 7
IQ - Iraq 7
LT - Lituania 7
MX - Messico 7
TW - Taiwan 7
NG - Nigeria 6
TN - Tunisia 6
CO - Colombia 5
DK - Danimarca 5
MD - Moldavia 5
NO - Norvegia 5
PT - Portogallo 5
TH - Thailandia 5
AE - Emirati Arabi Uniti 4
AR - Argentina 4
BG - Bulgaria 4
RS - Serbia 4
EE - Estonia 3
HU - Ungheria 3
JO - Giordania 3
LA - Repubblica Popolare Democratica del Laos 3
LU - Lussemburgo 3
LV - Lettonia 3
MA - Marocco 3
NP - Nepal 3
SD - Sudan 3
CM - Camerun 2
KE - Kenya 2
LK - Sri Lanka 2
MG - Madagascar 2
MO - Macao, regione amministrativa speciale della Cina 2
NZ - Nuova Zelanda 2
PA - Panama 2
SC - Seychelles 2
SI - Slovenia 2
A1 - Anonimo 1
AL - Albania 1
AM - Armenia 1
BH - Bahrain 1
BO - Bolivia 1
BZ - Belize 1
CR - Costa Rica 1
EC - Ecuador 1
GE - Georgia 1
KW - Kuwait 1
MK - Macedonia 1
MM - Myanmar 1
PE - Perù 1
PR - Porto Rico 1
SK - Slovacchia (Repubblica Slovacca) 1
TT - Trinidad e Tobago 1
Totale 14.243
Città #
Chandler 1.263
Ashburn 532
Singapore 531
Warsaw 460
Dublin 371
Fairfield 244
Ann Arbor 234
Jakarta 234
Wilmington 234
Dearborn 225
Jacksonville 212
San Mateo 204
Woodbridge 193
New York 180
Rome 180
Nanjing 163
Houston 160
Seattle 143
Milan 140
Boston 136
Beijing 132
Cattolica 126
Princeton 111
Bremen 95
Moscow 92
Cambridge 82
Marseille 78
Lawrence 77
Chicago 71
Helsinki 70
Redwood City 63
Brussels 62
Munich 53
Pune 51
Abidjan 49
Boardman 49
Izmir 47
Nanchang 46
Los Angeles 44
Norwalk 41
Hong Kong 39
Hangzhou 35
Kunming 33
Redmond 33
London 32
Hebei 31
Falls Church 27
Shanghai 27
Shenyang 27
Toronto 27
Guangzhou 26
Lancaster 26
Mountain View 26
Tianjin 24
Brno 23
Hefei 23
Jiaxing 23
Nürnberg 23
Augusta 20
Andover 19
Changsha 19
Falkenstein 19
Kraków 19
Washington 18
Jinan 17
Leawood 17
Busto Arsizio 16
Kish 16
University Park 16
Frankfurt am Main 15
Ottawa 15
Zhengzhou 15
Paris 14
San Diego 14
Tokyo 14
Santa Maria 12
Amsterdam 11
Dammam 11
Detroit 11
Palermo 11
Simi Valley 11
Zurich 11
Fremont 10
Naples 10
Chengdu 9
Delhi 9
Haikou 9
Lappeenranta 9
Ningbo 9
Phoenix 9
Sydney 9
Vancouver 9
Wuhan 9
Bari 8
Dong Ket 8
Fuzhou 8
Mumbai 8
Al Qatif 7
Ardabil 7
Cagliari 7
Totale 8.498
Nome #
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 432
Porphyromonas gingivalis and the pathogenesis of rheumatoid arthritis: analysis of various compartments including the synovial tissue 382
The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU) 322
MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis 299
Overweight/obesity affects histological features and inflammatory gene signature of synovial membrane of Rheumatoid Arthritis 273
Differential synovial tissue biomarkers among psoriatic arthritis and rheumatoid factor/anti-citrulline antibody-negative rheumatoid arthritis 261
MicroRNA-155-at the Critical Interface of Innate and Adaptive Immunity in Arthritis. 207
B cell subsets in the joint compartments of seropositive and seronegative RA and non-RA arthritides express memory markers and ZAP-70 and characterize the aggregate pattern irrespectively of the autoantibody status. 194
Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis. 167
MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis 139
B-cell subsets in the joint compartments of seropositive and seronegative rheumatoid arthritis (RA) and No-RA arthritides express memory markers and ZAP70 and characterize the aggregate pattern irrespectively of the autoantibody status 138
Porphyromonas gingivalis and the pathogenesis of rheumatoid arthritis: analysis of various compartments including the synovial tissue. 137
Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis 135
Very early rheumatoid arthritis is the major predictor of major outcome: clinical ACR remission and radiographic non-progression. 126
The role of High-mobility group box protein 1 in collagen antibody-induced arthritis is dependent on Vascular endothelial growth factor. 125
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 125
ZAP-70+ B Cell Subset Influences Response to B Cell Depletion Therapy and Early Repopulation in Rheumatoid Arthritis 122
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 121
Proton pump inhibitors in rheumatic diseases: clinical practice, drug interactions, bone fractures and risk of infections 119
Memory B cell subsets and plasmablasts are lower in early than in long-standing rheumatoid arthritis 119
Detection of bone erosions in early rheumatoid arthritis: 3D ultrasonography versus computed tomography 115
Has shoulder ultrasonography got a predictive value in Polymialgia Rheumatica. In: EULAR. 114
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 114
Body weight, gender and response to TNF-α blockers in axial spondyloarthritis 113
Allele *2 of the HS1,2A enhancer of the Ig regulatory region associates with rheumatoid arthritis 111
Adult onset Still's disease and pregnancy 110
An autosomal recessive DNASE1L3-related autoimmune disease with unusual clinical presentation mimicking systemic lupus erythematosus 108
Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission 102
Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis. 97
IL COINVOLGIMENTO ARTICOLARE NEL LES: LA FORMA CLASSICA E LA VARIANTE “RHUPUS” 97
Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: A clue to interpret different chances of relapse after clinical remission? 94
Chemerin and PEDF are metaflammation-related biomarkers of disease activity and obesity in rheumatoid arthritis 91
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 90
PTPN22 1858C>T polymorphism distribution in Europe and association with rheumatoid arthritis: case-control study and meta-analysis 89
Haemophilus parasuis (Glaesserella parasuis) as a Potential Driver of Molecular Mimicry and Inflammation in Rheumatoid Arthritis 89
Collagen Specific T-Cell Repertoire and HLA-DR Alleles: Biomarkers of Active Refractory Rheumatoid Arthritis 88
Collagen Specific T-Cell Repertoire and HLA-DR Alleles: Biomarkers of Active Refractory Rheumatoid Arthritis 87
Quantitative and semi-quantitative computed tomography analysis of interstitial lung disease associated with systemic sclerosis: A longitudinal evaluation of pulmonary parenchyma and vessels 87
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 86
Biomolecular features of inflammation in obese rheumatoid arthritis patients: management considerations 85
Body weight, gender and response to TNF-α blockers in axial spondyloarthritis 85
Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy 84
Biomarkers of Good EULAR Response to the B Cell Depletion Therapy in All Seropositive Rheumatoid Arthritis Patients: Clues for the Pathogenesis 84
Baseline shoulder ultrasonography is not a predictive marker of response to glucocorticoids in patients with polymyalgia rheumatica: A 12-month followup study 83
Synovial tissue derived characteristics are included in a nomogram for the prediction of treatment response in naïve Rheumatoid Arthritis 83
Five-year survival on infliximab in rheumatoid arthritis patients: analysis from an Italian registry (GISEA) by different calendar years 82
Sarilumab use in severe SARS-CoV-2 pneumonia 80
Is Citrullination Required for the Presence of Restricted Clonotypes Reacting With Type II Collagen? Comment on the Article by Chemin et al 79
Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study 79
Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression. 77
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register 76
Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus 76
The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk 75
Immunosuppressive Therapy (Methotrexate or Cyclophosphamide) in Combination with Corticosteroids in the Treatment of Giant Cell Arteritis: Comparison with Corticosteroids Alone 73
Selective Inhibitors of T Cell Receptor Recognition of Antigen–MHC Complexes for Rheumatoid Arthritis 73
Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases) 72
Residual respiratory impairment after COVID-19 pneumonia 72
Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study 71
Polymorphisms of the IgH enhancer HS1.2 and risk of systemic lupus erythematosus 71
Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. 71
No higher risk of respiratory symptoms in Italian rheumatological patients under IL-6R-inhibitor therapy in SARS-CoV-2 pandemic 70
Comparative analysis of synovial inflammation after SARS-CoV-2 infection 70
Systemic Bone Density at Disease Onset Is Associated With Joint Erosion Progression in Early Naive to Treatment Rheumatoid Arthritis: A Prospective 12-Month Follow-Up Open-Label Study 70
Validation of the classification criteria for cryoglobulinaemic vasculitis 69
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 69
Body weight, gender and response to TNF-α blockers in axial spondyloarthritis 68
Collagen Specific T-Cell Repertoire and HLA-DR Alleles: Biomarkers of Active Refractory Rheumatoid Arthritis 68
CTLA-4 Ig as an effective treatment in a patient with type I diabetes mellitus and seropositive rheumatoid arthritis 68
Association between the response to B cell depletion therapy and the allele*2 of the HS1,2A enhancer in seropositive rheumatoid arthritis patients 67
CTLA-4 Ig as an effective treatment in a patient with type I diabetes mellitus and seropositive rheumatoid arthritis 67
Simultaneous onset of mycobacterium kansasii pulmonary infection and systemic lupus erythematosus: A case report 67
Psychological Distress After Covid-19 Recovery: Reciprocal Effects With Temperament and Emotional Dysregulation. An Exploratory Study of Patients Over 60 Years of Age Assessed in a Post-acute Care Service 67
Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis 66
Adult Onset Still's Disease and Radiotherapy treatment for breast cancer: Case report about management of this rare association and literature review 66
Rheumatoid arthritis and Alzheimer's disease: genetic and epigenetic links in inflammatory regulation 65
Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease 65
Is it necessary to be citrullinated to have restricted clonotypes reacting with Collagen type II? Comment to article "A novel HLA-DRB1*10:01 restricted T cell epitope from citrullinated type II collagen relevant for Rheumatoid Arthritis" 64
Interleukin-6 and IgA-rheumatoid factor are crucial for baseline erosiveness, and anti-citrullinated peptide antibodies for radiographic progression in early rheumatoid arthritis treated according to a treat-to-target strategy 64
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort 64
Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial 63
Do we need to apply a T2T strategy even in ACPA-negative early rheumatoid arthritis? YES 63
Free light chains of immunoglobulins in patients with systemic sclerosis: correlations with lung involvement and inflammatory milieu 63
Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response. 63
Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement 62
Correction to: Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: influence of the disease severity and therapy on the ovarian reserve (Endocrine, (2019), 63, 2, (369-375), 10.1007/s12020-018-1783-1) 62
Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: Influence of the disease severity and therapy on the ovarian reserve 61
Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: Data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) Study Group 61
Position paper of Italian rheumatologists on the use of biosimilar drugs 60
Abatacept in the treatment of psoriatic arthritis: biological and clinical profiles (of the responders). 60
Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset still's disease: A multicentre retrospective observational study 60
Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis 59
Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study 59
B cell activating factor (BAFF) and BAFF receptors: fakes and facts 59
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 59
Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations 59
Synovial predictors of differentiation to definite arthritis in patients with seronegative undifferentiated peripheral inflammatory arthritis: MicroRNA signature, histological, and ultrasound features 58
An unusual lung involvement in scleroderma: lipoid pneumonia 58
Residual respiratory impairment after COVID-19 pneumonia 57
Pathogenetic, clinical and pharmaco-economic assessment in rheumatoid arthritis (RA) 57
Weight Loss, The Obesity Paradox in Rheumatoid Arthritis: Is It a Paradox? Comment on the Article by Baker et al 57
Totale 9.990
Categoria #
all - tutte 75.473
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.473


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020984 0 0 0 0 0 248 146 112 109 100 166 103
2020/20211.425 100 111 251 103 147 87 114 21 164 98 187 42
2021/20221.752 198 110 56 104 110 54 40 224 88 127 258 383
2022/20233.979 450 465 353 665 322 508 192 277 444 97 126 80
2023/20242.170 85 544 82 98 89 337 187 85 34 112 283 234
2024/20251.232 100 101 348 171 351 161 0 0 0 0 0 0
Totale 14.569